These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29789049)

  • 1. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based study of dosing and persistence with anti-dementia medications.
    Brewer L; Bennett K; McGreevy C; Williams D
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1467-75. PubMed ID: 23443628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
    Lachaine J; Beauchemin C; Crochard A; Bineau S
    Can J Psychiatry; 2013 Apr; 58(4):195-200. PubMed ID: 23547642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of acetyl cholinesterase inhibitors and memantine in nursing home residents.
    Gorus E; Van Puyvelde K; Corremans V; Mets T
    Acta Clin Belg; 2011; 66(5):361-6. PubMed ID: 22145270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Cholinesterase Inhibitors Increases Initiation of Urinary Anticholinergics in Persons with Alzheimer's Disease.
    Lampela P; Taipale H; Hartikainen S
    J Am Geriatr Soc; 2016 Jul; 64(7):1510-2. PubMed ID: 27401848
    [No Abstract]   [Full Text] [Related]  

  • 12. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
    [No Abstract]   [Full Text] [Related]  

  • 14. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
    Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
    JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in diagnostic process, treatment and social Support for Alzheimer's dementia between primary and specialist care: resultss from the Swedish Dementia Registry.
    Garcia-Ptacek S; Modéer IN; Kåreholt I; Fereshtehnejad SM; Farahmand B; Religa D; Eriksdotter M
    Age Ageing; 2017 Mar; 46(2):314-319. PubMed ID: 27810851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.